Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 4/20 | 0.36 |
| ▸ | HTR2C | P28335 | 4/20 | 0.36 |
| ▸ | HTR2B | P41595 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | RNF114 | Q9Y508 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | YAP1 | P46937 | 2/20 | 0.34 |
| ▸ | TEAD4 | Q15561 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3464583 | 0.87 | DPP4 (0.50) | DPP4DPP7YAP1TEAD4 | |
| SCHEMBL3338258 | 0.81 | LMNA (0.44) | DPP4DPP7HTR2AHTR2CHTR2B | |
| SCHEMBL27551341 | 0.75 | DPP4 (0.38) | DPP4DPP7HTR2AHTR2CHTR2B | |
| SCHEMBL18284789 | 0.73 | MEN1 (0.52) | DPP4DPP7 | |
| SCHEMBL7467909 | 0.72 | DPP4 (0.54) | DPP4DPP7HTR2AHTR2CHTR2B | |
| SCHEMBL9235802 | 0.71 | DPP4 (0.42) | DPP4DPP7 | |
| SCHEMBL7400548 | 0.71 | MAOB (0.39) | HTR2AHTR2CHTR2BESR1ESR2 | |
| SCHEMBL27551343 | 0.71 | DPP4 (0.33) | DPP4DPP7HTR2AHTR2CHTR2B | |
| SCHEMBL3314580 | 0.71 | DPP4 (0.53) | DPP4DPP7HTR2AHTR2CHTR2B | |
| SCHEMBL20528485 | 0.70 | DPP4 (0.46) | DPP4DPP7HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1007524-B1 | INDOLE DERIVATIVES AS 5-HT1B AND 5-HT1D AGONISTS | PF MEDICAMENT (FR) | 2003-11-12 | — | — | EP | disclosed |
| US-6589953-B2 | Treatment of anxiety, depression, aggressiveness, panic attacks, obsessive-compulsive disorders, schizophrenia, suicidal tendency, neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease | PIERRE FABRE MEDICAMENT (FR) | 2003-07-08 | — | — | US | disclosed |
| US-20020061891-A1 | Indole derivatives as 5-HT1B and 5-HT1D agonists | PEREZ MICHEL (FR) | 2002-05-23 | — | — | US | disclosed |
| US-6277853-B1 | FOR TREATMENT OF NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS, MIGRAINES, ALCOHOLISM | PIERRE FABRE MEDICAMENT (FR) | 2001-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061891-A1 | Indole derivatives as 5-HT1B and 5-HT1D agonists | HTR1B, HTR1A, HTR1D | DPP4 2506/4885DPP7 2193/4885HTR2A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.